A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Stopped Due to a change in the Sponsor's corporate strategy the study was terminated early by the Sponsor prior to enrollment into the dose expansion part of the study (Part B).

Conditions

• Solid Tumor, Adult
• Intrahepatic Cholangiocarcinoma
• Urothelial Carcinoma

Interventions

• DRUG: KIN-3248

Sponsor

Kinnate Biopharma